Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A new facility opened in Wallingford Saturday afternoon that treats mental health conditions with low doses of Ketamine.

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...